• Home
  • Current Clients
  • Client List
  • Clients In the News
    • 2020 News Releases >
      • Aerial BioPharma JZP-110 Jan 2020
    • 2019 News Releases >
      • Emergo Therapeutics Aug 2019
      • Emergo Therapeutics May 2019
      • Emergo Therapeutics April 2019
      • Aerial BioPharma JZP-110 March 2019
    • 2018 News Releases >
      • Emergo Therapeutics 2018
    • 2017 News Releases >
      • Aerial BioPharma JZP-110 Dec
    • 2016 News Releases >
      • Target PharmaSolutions Nov
      • Target PharmaSolutions Oct
      • Arrivo BIoVentures
      • Contego Medical
    • 2015 News Releases >
      • Contego Medical
      • AMAG Pharmaceuticals Announces Further Expansion of Maternal Health Portfolio
      • Chapel Hill’s Achelios reports promising test results
    • 2014 News Releases >
      • Jazz Pharmaceuticals Announces Acquisition From Aerial Biopharma Of Rights To A Late Stage Investigational Compound
      • Aerial Hears a Cool Jazz $400M Wake-Up Call
    • 2013 News Releases >
      • TBJ 2013 Life Sciences Awards winners revealed
      • Aerial Biopharma Announces Closing of Second Tranche of Series A
    • 2012 News Releases >
      • Acorda Therapeutics Announces Completion of Neuronex, Inc. Acquisition
      • Aerial Biopbarma Receives FDA Orpban Drug Designation
      • A new migraine drug taken by skin? How Achelios could make it happen
      • Acorda 4Q profit climbs; company buying Neuronex
      • Addrenex Founders Sell Neuronex
    • 2011 News Releases >
      • Lookout Capital Announces Investment In EnviCor
  • Interests
  • Contact me
  KJA Associates, LLC - part-time CFO services

DURHAM, N.C., May 30, 2019 /PRNewswire/ -- Emergo Therapeutics, which continues to accelerate its lead candidate norketotifen through Phase 2 studies, has added another seasoned executive to its Board of Directors. Jack Bailey, President, US Pharmaceuticals at GlaxoSmithKline, joined the Board on May 17, 2019. Moise Khayrallah, PhD, CEO and Chairman of the Board, Meg Powell, PharmD, Co-Founder of Target Pharma Solutions, and Bobby Helmedag, Managing Director, Rex Health Ventures, will continue to serve with Bailey.

"We are thrilled to have Jack at the table with us and look forward to his contributions in driving Emergo Therapeutics to success. Jack's addition to our board is a strong signal of good things to come from our team here at Emergo.  With Jack's help, we will continue to meet and exceed our aggressive internal timelines for the development of our lead compound, norketotifen, for influenza and influenza-like illness (ILI)," Dr. Khayrallah said.

Jack Bailey commented on the appointment, "Moise has assembled an excellent team that is focused around our common goal. I am excited to join my fellow board members and offer my support in moving Emergo Therapeutics closer to the goal of providing some relief to patients."

About Emergo Therapeutics
Emergo Therapeutics (http://emergotherapeutics.com/) is focused on developing drugs that reduce inflammation and improve immune system function in various indications, starting with infectious diseases.  Emergo's lead program is the development of norketotifen for the treatment of uncomplicated influenza and influenza‑like illness (ILI).

Contact:
Henry (Hank) McCarthy II
Vice President, Business Development
Emergo Therapeutics, Inc.
6208 Fayetteville Road, Suite 104
Durham, NC 27713
+1 (984) 377-5151
SOURCE Emergo Therapeutics

Related Links http://emergotherapeutics.com
  • Home
  • Current Clients
  • Client List
  • Clients In the News
    • 2020 News Releases >
      • Aerial BioPharma JZP-110 Jan 2020
    • 2019 News Releases >
      • Emergo Therapeutics Aug 2019
      • Emergo Therapeutics May 2019
      • Emergo Therapeutics April 2019
      • Aerial BioPharma JZP-110 March 2019
    • 2018 News Releases >
      • Emergo Therapeutics 2018
    • 2017 News Releases >
      • Aerial BioPharma JZP-110 Dec
    • 2016 News Releases >
      • Target PharmaSolutions Nov
      • Target PharmaSolutions Oct
      • Arrivo BIoVentures
      • Contego Medical
    • 2015 News Releases >
      • Contego Medical
      • AMAG Pharmaceuticals Announces Further Expansion of Maternal Health Portfolio
      • Chapel Hill’s Achelios reports promising test results
    • 2014 News Releases >
      • Jazz Pharmaceuticals Announces Acquisition From Aerial Biopharma Of Rights To A Late Stage Investigational Compound
      • Aerial Hears a Cool Jazz $400M Wake-Up Call
    • 2013 News Releases >
      • TBJ 2013 Life Sciences Awards winners revealed
      • Aerial Biopharma Announces Closing of Second Tranche of Series A
    • 2012 News Releases >
      • Acorda Therapeutics Announces Completion of Neuronex, Inc. Acquisition
      • Aerial Biopbarma Receives FDA Orpban Drug Designation
      • A new migraine drug taken by skin? How Achelios could make it happen
      • Acorda 4Q profit climbs; company buying Neuronex
      • Addrenex Founders Sell Neuronex
    • 2011 News Releases >
      • Lookout Capital Announces Investment In EnviCor
  • Interests
  • Contact me